Ninety One UK Ltd trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 825,284 shares of the medical research company’s stock after selling 46,501 shares during the period. Thermo Fisher Scientific makes up approximately 1.0% of Ninety One UK Ltd’s investment portfolio, making the stock its 25th largest holding. Ninety One UK Ltd owned 0.21% of Thermo Fisher Scientific worth $299,033,000 at the end of the most recent reporting period.
Several other hedge funds have also recently bought and sold shares of TMO. Proffitt & Goodson Inc. bought a new stake in shares of Thermo Fisher Scientific in the second quarter worth $35,000. Stonehage Fleming Financial Services Holdings Ltd acquired a new stake in Thermo Fisher Scientific in the 1st quarter valued at $28,000. HWG Holdings LP bought a new stake in Thermo Fisher Scientific during the 2nd quarter worth about $36,000. Liberty One Investment Management LLC acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth about $41,000. Finally, JJJ Advisors Inc. grew its holdings in shares of Thermo Fisher Scientific by 36.5% in the 2nd quarter. JJJ Advisors Inc. now owns 116 shares of the medical research company’s stock valued at $42,000 after acquiring an additional 31 shares in the last quarter. 88.12% of the stock is owned by institutional investors.
TMO has been the subject of several recent research reports. SVB Leerink increased their price target on Thermo Fisher Scientific from $455.00 to $470.00 and gave the company an “outperform” rating in a research report on Friday. Cleveland Research raised shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research note on Wednesday, July 15th. JPMorgan Chase & Co. restated an “overweight” rating and set a $460.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, August 20th. Robert W. Baird increased their price target on shares of Thermo Fisher Scientific from $352.00 to $436.00 in a research note on Thursday, July 23rd. Finally, Needham & Company LLC initiated coverage on shares of Thermo Fisher Scientific in a research note on Thursday, August 13th. They set a “buy” rating and a $468.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $447.21.
Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 22nd. The medical research company reported $3.89 EPS for the quarter, beating the consensus estimate of $2.67 by $1.22. The company had revenue of $6.92 billion for the quarter, compared to the consensus estimate of $6.91 billion. Thermo Fisher Scientific had a return on equity of 18.18% and a net margin of 14.12%. During the same quarter in the prior year, the business earned $3.04 earnings per share. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 15.27 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 0.20%. The ex-dividend date of this dividend is Monday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is 7.13%.
In other Thermo Fisher Scientific news, VP Syed A. Jafry sold 20,513 shares of the stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $414.94, for a total transaction of $8,511,664.22. Following the transaction, the vice president now owns 26,657 shares in the company, valued at approximately $11,061,055.58. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Peter E. Hornstra sold 3,337 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $418.82, for a total transaction of $1,397,602.34. Following the transaction, the chief accounting officer now owns 19,862 shares in the company, valued at approximately $8,318,602.84. The disclosure for this sale can be found here. Insiders have sold a total of 173,868 shares of company stock worth $71,253,379 in the last quarter. Company insiders own 0.44% of the company’s stock.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Recommended Story: What is included in the gross domestic product?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.